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Abstract
The pulsed release of three antidepressants (paroxetine, duloxetine, vortioxetine), loaded on two vinyl hydrogels bearing -amino acid residues (L-phenylalanine, 
L-valine) and embedded magnetic nanoparticles, was evaluated in different buffer solutions of purposely chosen pHs (2.9, 4.6, and 7.4). At low pH values the release 
of the drug was always small for a long period of days, and it underwent a sudden increase when a solution of pH 7.4 was maintained for a short period of hours. The 
releasing increase becomes much higher as greater was the residence time of the solution in contact with the hydrogel. The application of an alternating magnetic field 
(AMF) further increases the amount of drug released during the pH pulses. These different release variations were related to a different and reversible ability to swell 
of the hydrogel. The mechanism behind the process was mainly due to the different acid/base behaviour of the free carboxyl groups.
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Abbreviations
AMF: Alternating magnetic field; EDS:  Equilibrium degree of 
swelling; MDD: Major depressive disorder; SSRI:  Selective serotonin 
reuptake inhibitors; EBA: N,N’-ethylene-bisacrylamide; PHE-
Nip3: Poly(N-acryloyl-L-phenylalanine-co-N-isopropylacrylamide) 
hydrogel; AVA-5: Poly(N-acryloyl-L-valine) hydrogel crosslinked 
with 5 mol% of EBA; AVA-2:  Poly(N-acryloyl-L-valine) hydrogel 
crosslinked with 2 mol% of EBA 
Introduction
In recent years we have proposed some polyelectrolyte hydrogels, 
of anionic and ampholyte nature, capable of complexing, besides 
metal ions, with metal-based drugs and drug molecules containing 
amino functionality [1-3]. The main polymer structure bearing 
residues of -amino acids (L-phenylalanine, L-valine, L-histidine) was 
cross-linked with different cross-linking agents and copolymerized 
with N-isopropylacrylamide (NIPAAm). In some cases, magnetic 
nanoparticles have been incorporated to make the hydrogel a multi-
responsive nanocomposite sensitive to both direct (pH, temperature, 
ionic strength) and remote (alternating magnetic fields, AMF) 
stimulations [3,4-6]. In the ionized state some of these hydrogels exhibit 
an exceptionally high degree of swelling, the magnitude of which can be 
monitored by the ionic strength, temperature and pH. In fact, anionic 
hydrogels show different critical conditions at which the whole swollen 
mass completely collapse at pH 4 and pH 5 due to the compounds 
bearing the L-valine and the L-phenylalanine residues, respectively 
[1-3]. Such critical pH values are related to their thermodynamic 
properties, as revealed from the study of the free polymers in aqueous 
solution [7-8]. A partial neutralization of the ionized carboxyl groups 
allows the shrinking of the macromolecular structure, as hydrophobic 
interactions outweight the electrostatic repulsion. Typically, the 
swollen hydrogel undergoes a rapid collapse in the presence of cationic 
drugs and this collapse is the more rapid and complete the larger is 
the basicity constant of the drug itself [2,9]. The main drug-polymer 
interaction was reported to be of ionic nature, although hydrophobic 
interactions cannot be excluded. It follows that the drug-polymer 
strength affects the whole drug release process; the free drug, that is in 
equilibrium with the adduct, must spread through the network to be 
used for therapeutic purposes. A further advantage is the load of the 
drug within the hydrogel, which preserves its effectiveness over time. 
This was evidenced by previous results for the ‘in vitro’ release study of 
anticancers (cis-platinum, doxorubicin) [10,11], glaucoma treatment 
(pilocarpine) [12] and, not finally, of antidepressants (citalopram, 
trazodone, paroxetine, duloxetine) [5,9]. In all cases, the typical 
release profiles showed that the drug concentration is maintained in 
the therapeutic window for an extended period of time, ensuring the 
sustained therapeutic action. In some cases, the need to promote a drug 
concentration in solution is ensured by the increasing temperature 
and by the application of the appropriate AMF stimulation; thus, ‘on 
demand’ may be released a greater amount of drug to the target organ to 
alleviate the medical needs of the moment and to restore a normal state 
of health [2,4,5]. Besides the sustained release formulation, the pulsatile 
system may benefit from a therapy mainly because it is linked with the 
circadian rhythms of the body [13,14]. Peppas et al. reported one of the 
first example of pulsatile local delivery of thrombolytic (streptokinase) 
and antithrombotic (heparin) drugs using temperature/pH responsive 
hydrogels based on NIPAAm copolymerized with methacrylic acid 
[15,16].  The hydrogels improved the pulsatile streptokinase release and 
the release rate between the swollen and collapsed hydrogel states was 
at least one order of magnitude different. Because of the many diseases 
that follow the circadian rhythms of the body, the goal in drug delivery 
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research is to develop formulations to meet therapeutic needs relating 
to particular pathological conditions. Researchers have addressed 
the question of creating new stimuli-responsive hydrogels as carriers 
for drug delivery systems because their unique physicochemical and 
biological properties can protect sensitive drugs [17,18]. Based on the 
externally triggered ability, the use of stimuli-responsive hydrogels can 
be associated with the events of the circadian rhythm that cause the 
release of a drug at predetermined intervals. 
Following our interest in the release of antidepressants, this 
paper is concerning with the results of the pulsed release behaviour 
of three drugs (Scheme 1: paroxetine, duloxetine, vortioxetine) by 
nanocomposite hydrogels used previously. 
Depression is a common illness worldwide and can happen to 
anybody; it causes mental anguish and affects people’s ability to carry 
out everyday tasks [19]. Recently, the World Health Organization has 
estimated more than 300 million people to be affected and, for this 
purpose, has launched a one-year campaign to ensure that more people 
with depression both seek and get help [20]. Fortunately, depression can 
be prevented and treated adequately. For the treatment of the disease, 
the three drugs mentioned above are specific and used today in the 
clinical practice. Like the paroxetine, both duloxetine and vortioxetine 
are two new antidepressant drugs that have been used clinically in the 
treatment of major depressive disorder (MDD) [21]. A variety of meta 
analyses have been conducted to evaluate the efficacy and tolerability of 
these three drugs in depression treatment [22]. It was concluded that, 
whereas the paroxetine is superior or equivalent to placebo and that it 
is equivalent or inferior to other antidepressants, duloxetine was more 
effective but less well-tolerated than vortioxetine [23]. Antidepressants, 
of a basic nature for the presence of the secondary amino nitrogen 
atom, were loaded on two anionic polyelectrolyte hydrogels bearing 
L-phenylalanine (PHE-Nip3) and/or L-valine (AVa-5) residues [9]. 
While the first platform is formed by a copolymer (poly-N-acryloyl-
L-phenylalanine-co-NIPAAm in a molar ratio of one and crosslinked 
with N,N’-ethylene-bis-acrylamide, EBA, of 2 mol%), the second one 
consists of a homopolymer (poly-N-acryloyl-L-valine) crosslinked 
with EBA of 5 mol%. In addition, the hydrogel PHE-Nip3 contains 
embedded magnetic nanoparticles (CoFe2O4) [4]. 
With the same drug, the different thermodynamic properties of the 
polymer enable the design of drug carrier systems that are best suited to 
the application purpose. The release of antidepressants was conducted 
in aqueous solution of acid pH for a long period of time with a short 
overlap period of regular pulses at basic pH. In this short time interval, 
the hydrogel is subjected to the stimulus of a high pH value that 
involves two simultaneous processes: a) an increase in swellability and 
b) a chemical equilibrium displacement towards the dissociation of the 
drug bound to the polymer. The return to low acidic pH conditions 
restores the low swelling/collapse of the network with a minor drug 
loading. In this work it is reported the pulsed release behaviour of some 
antidepressant drugs, of interest as a template for the design of all the 
transport systems of drugs for the therapy of diseases which follow the 
circadian rhythms of the body [24].
Results and discussion  
Pulsed release of paroxetine
Paroxetine is an antidepressant belonging to the class of Selective 
Serotonin Reuptake Inhibitors (SSRI) [25]. Due to its efficacy and 
good tolerability, it is commonly used in the treatment of MDD [21]. 
In particular, for its marked sedative effect, it has successfully been 
demonstrated to improve mood disorders with anxiety characteristics 
and/or even anxiety disorders such as panic disorder, generalised anxiety 
and social fobia, at a dosage ranging from 20 to 60 mg/day. The main side 
effects are attributable to an anticholinergic feature responsible for dry 
mouth, constipation, sedation; for the same reason it is controindicated 
in case of glaucoma and benignal prostatic hypertrophy. Nausea could 
occur in the first weeks of treatment with paroxetine and it could be 
prevented by a full stomach administration. Sedation often requires 
an evening administration. No risk for addiction or tolerance occur 
but, due to its short half-life, discontinuation symptoms (such as 
nausea, headache, dizziness, sleep problems, anxiety) could appear if 
a slow dosage reduction is not provided. Thus, a long-lasting sustained 
release of the drug could go beyond this limit. The pulsed release of 
the paroxetine from hydrogels PHE-Nip3 and AVA-5 was analyzed 
in a period of time long enough (at least two weeks) in two acidic 
pH solutions (pH 2.9 and 4.6). At set intervals of time, the external 
acid solution was replaced by a physiological pH solution (PBS, pH 
7.40) for a short period of time (1 or 2 hours). The choice of these 
pH values was dictated by the swelling behaviour of the hydrogels, 
as previously reported [2,9]. While the thermodynamic properties of 
the hydrogel PHE-Nip3 showed a critical point of collapse at pH 5, 
the hydrogel AVA-5 involves a collapse at pH 4. The basic difference 
is to be attributed to the chemical structure of the two polymers. In 
fact, while the completely ionized and swollen hydrogel carrying the 
L-phenylalanine residues show a shrinking phenomenon at a degree 
of protonation  = 0.3, the hydrogel with the L-valine residues shrinks 
to  value of about twice [9]. The different behaviour was attributed to 
the greater hydrophobic attraction effect which clearly exceeds the ion 
repulsive effect exerted by the remaining COO- groups, and this, for 
the hydrogel PHE-Nip3, is early compared to the hydrogel AVA-5. So, 
for the two hydrogels it is to expect a more swollen state at pH 7.4, and 
a state of collapse at pH 2.9; on the other hand, at pH 4.6 a collapsed 
state should only occur for the hydrogel PHE-Nip3. Moreover, the 
presence of the ionized drug substantially contributes to maintain the 
hydrogel in the collapsed state because of its ionic interaction with the 
carboxylic groups. This is evident in any case since the formation of 
the drug-hydrogel adduct leads to the complete collapse of the ionic 
and swollen hydrogel in presence of the hydrochloride drug solution 
[4,5,9]. Additionally, despite the non-swellability at acid pH, the 
hydrogel loaded with the drug is wettable and capable of releasing the 
drug itself in a slow way and controllable by external stimuli.
In Figure 1 is shown the comparison of the pulsed release of the 
paroxetine from the hydrogel PHE-Nip3 in two different aqueous 
solutions of pH 2.9 and 4.6, with the pH pulse 7.4 for 1 hour. In addition 
to pH 4.6, it is shown a comparison with the pulse of pH 7.4 for 2 hours. 
In all cases, the additional stimulation of the alternating magnetic field 
(AMF) is compared. 
From the beginning it is immediately evident that the release of 
the drug is greater in the more acidic solution (pH 2.9) and that the 
released quantity becomes significantly higher when an appropriate 
external AMF of low frequency (20 kHz, 50W) is applied. In general, 
the application of the AMF produces an increase in the percentage 
of release, especially at the first stage of the pulsed release [2,9].  This 
because the energy induced by the AMF can cause an improved 
permeability control mechanism due to oscillation or vibration of the 
network-embedded CoFe2O4 magnetic nanoparticles [4,6]. This in 
turn may cause twisting and/or displacement of the polymeric chains, 
resulting in an enhancement of the diffusion process. According to other 
researchers, the magnetically-induced deformation of the hydrogel is a 
result of the elastic oscillation or vibration of the embedded magnetic 
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Scheme 1. Chemical structure of antidepressant drugs.
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Figure 1. Release of paroxetine (%) from the hydrogel PHE-Nip3 in buffered solutions (pH 4.60: pink rhomboidal and light blue circles; pH 2.9: red squares) with PBS (pH 7.40) pulsed 
variations of 1h (pink, red) and 2h (light blue) without (left panel) and with (right panel) AMF applications (20kHz/50W) at 25°C. The results are the average of at least two experiments 
with less than 3% error. 
nanoparticles resulting in mechanical deformation of the hydrogel 
to squeeze out the drug (26-28). On the other hand, the release into 
solution at pH 4.6 is significantly lower for a long period of time. Only 
the change of external solution to pH 7.4 (first pH pulse of 1 hour) leads 
to a significant increase in the paroxetine release which is even greater if 
the residence time in contact with the hydrogel is doubled to two hours: 
compared with 1-hour, pulses of 2-hours ensure a higher percentage of 
the drug in solution. The return to conditions of acidic pH (2.9 and 4.6) 
restores the release for the successive period of days, while the further 
pulse to pH 7.4 reproduces the burst in drug release. Finally, in the last 
pH pulse performed at stage 3, the PBS solution at pH 7.4 has been in 
contact for a long period of days to allow the complete release of the 
drug from the hydrogel. This sustained release has required a few days, 
despite the speeding of the AMF force [9]. 
Of course, all the stepwise process is to be related to chemical 
equilibria of all ionic/ionizable species involved and their base strength. 
Paroxetine, being a strong base (logK 9.77) [9,29], remains mostly in 
the protonated state in all considered pH conditions. This species, 
interacting ionically to some extent with the ionized COO- groups of 
the swollen hydrogel, allows the collapse of the whole structure with the 
formation of a drug-polymer adduct of chemical stability. Possible pH 
variation of a solution containing the adduct may shift the protonation 
equilibrium of the hydrogel towards the ionised form if the pH > pKa 
(pKa of the hydrogel) [2,9] with the consequence of an increase in 
swellability and a greater release of the drug in solution; on the other 
hand, at pH < pKa the hydrogel involves a charge neutralization with 
a consequent shrinking phenomenon and a greater availability of the 
free drug in solution. All this is consistent with the data reported in 
Figure 1. 
We can find a support mechanism in the paroxetine release data 
from the hydrogel AVA-5 in the same pH conditions used for the 
hydrogel PHE-Nip3. As reported in Figure 2, once again the release of the 
drug at pH 2.9 was slightly higher than that experienced at pH 4.6, despite 
the greater swellability of the hydrogel AVA-5 at this latter pH [3,5,9,12]. 
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In fact, the greater swellability involves a burst release of paroxetine, 
as observed at the pH-pulse of 7.40; this does significantly increase the 
released amount for both 1h and 2h pulses. It is worth-noting that the 
greater cross-linked hydrogel AVA-5 releases a quantity of paroxetine 
comparable to that shown by the hydrogel PHE-Nip3 in the same 
conditions of pH and even under stimulation of the AMF. A minor 
release is only observed at pH 2.9 due to the compactness of the adduct 
and the greater value of pKa for the hydrogel AVA-5 [2,9].
At the end of each pulsed release process, the hydrogel showed a 
fairly constant swelling with values of equilibrium degree of swelling 
(EDS) between 30 and 35 for the hydrogel PHE-Nip3 and between 15 
and 20 for the hydrogel AVA-5. The value of the equilibrium degree of 
swelling (equation 1)
EDS = (Ww - Wd)/Wd                                                                                              (1)
(where Ww and Wd is the weight of wet and dry hydrogel, 
respectively) represents the state of the wettability of the hydrogel, 
i.e. the quantity of bound water per unit of dry weight of the hydrogel 
itself. Of course this depends on the pH value, as the gradual ionization 
of the hydrogel promotes its swelling. In all the intermediate stages, 
the EDS follows a trend connected to the pH and to the amount of the 
drug released at that stage. Figure 3 summarizes the results of the EDS 
values obtained for the release of paroxetine from the hydrogel PHE-
Nip3 at the three different pH values considered and with time-pulse 
of 1h and 2h. The same figure 3 shows for comparison the behaviour of 
the hydrogel AVA-5 in the same pH conditions.
At a first look it appears a reversible swelling-collapsing process 
for the hydrogel PHE-Nip3 when the pH varies from 2.9 (or 4.6) to 
7.4; a low value of EDS at acid pH is compatible with the complete 
charge neutralization of the network. The gradual release of the drug 
in the successive pulses at pH 7.4 improves the formation of free 
COO- groups that consequently leads to an increase in the hydrogel 
swellability. Though small, some significant changes in EDS can be 
observed in the AMF regime for pH pulses of 1h or 2h. The small 
increments of the EDS values  are in line with the increased release of 
the drug that results in greater ionization of the hydrogel, especially at 
pH 7.40. On the other hand, the hydrogel AVA-5, despite its greater 
cross-linking content, shows a clear trend of EDS which is confirming 
the hypothesis of a greater swelling for an increased ionisation, due to 
the release of the drug. Besides the clear reversibility observed for the 
swollen-collapse at pH 2.9, with pulse of 1h at pH 7.4, no collapse at 
pH 4.6 is observed, but rather there is an increased swellability in the 
subsequent pulses, with values of EDS at pH 7.4 always higher than 
those observed at pH 4.6. This trend is enhanced with a 2h pulse. Of 
course, this different behaviour of the two hydrogels is to be related to 
thermodynamic properties described above [2,9].
Pulsed release of duloxetine and vortioxetine
Duloxetine is an antidepressant drug belonging to the class of 
Serotonin-Norepinephrin Reuptake Inhibitors [30]. It is commonly 
used in the treatment of depression, mainly in case of anhedonia and 
lack of energy. Even if it is well tolerated, sometimes symptoms of 
anxiety and hyperactivation could occur, along with gastrointestinal 
symptoms, dizziness and sleep disorders. The usual therapeutic dosage 
ranges from 30 to 120 mg; particular attention could be paid in case of 
older patients, who would benefit from a lower dosage. Duloxetine has 
been approved also for the treatment of neuropathic pain, even with a 
lot of caution due to the high risk for switching in maniac episodes in 
people suffering from undiagnosed Bipolar Disorder [31].
Vortioxetine is a recent antidepressant molecule having a 
multifactorial mechanism of action [32,33]. It shows an action on 
serotonin receptors, as well as on other neurobiological targets 
such as norepinephrine, dopamine, acetylcholine and histamine 
neurotransmissions. This multimodal feature provides a therapy for 
mood and anxiety disorders, but it even improves cognitive function, 
allowing to reach the “Full Functional Recovery” in depressed patients 
and also demonstrating to be of interest in the treatment of elderly 
mood disorders. The usual dosage ranges from 5 to 20 mg; the low 
incidence of side effects (mainly nausea) makes this new molecule 
suitable for safe long-term treatment of MDD. Thanks to its long half-
life (66 hours), there is no risk for discontinuation symptoms.
In a similar manner to the release of paroxetine, the sustained 
release of duloxetine and vortioxetine by the hydrogel PHE-Nip3 was 
evaluated only at pH 4.60 with pulse of 2h at pH 7.40 and under similar 
magnetic stimulations (20 kHz and 50 W). Figure 4 summarizes the 
results obtained and compared with those of paroxetine reported 
above. 
Since the initial stage, at pH 4.60 it may see a release (%) of duloxetine 
and vortioxetine appreciably higher than that of paroxetine, and this is 
further improved in the AMF regime. With the application of the first 
pulse at pH 7.40, the burst release of duloxetine and vortioxetine clearly 
exceeds that observed for paroxetine; these, though in larger quantity, 
are leveled to the same amount shown in the AMF regime. From the 
second stage of pulse at pH 7.40, the release of vortioxetine is improved 
with respect to duloxetine, even if the effect of the AMF seems to be 
negligible in comparison to the superiority shown for the release of 
the paroxetine. In these release mechanisms, the strength of polymer-
drug interaction plays a key role; as we have reported the interaction 
is of electrostatic type, and is basically related to the pKa of the drug 
[29]. At the same base strength of the polymer, a high pKa value of 
the drug produces a stronger electrostatic interaction and therefore 
a lower tendency to release the same drug in solution in equilibrium 
with the drug-polymer adduct. The system under study shows that 
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Figure 2.  Release of paroxetine (%) from the hydrogel AVA-5 in buffered solution (pH 
4.60: pink rhomboidal and light blue circles; pH 2.9: red squares) with PBS (pH 7.40) 
pulsed variations of 1h (pink, red) and 2h (light blue) at 25°C. The results are the average 
of at least two experiments with less than 3% error.
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(2.9: orange; 4.6: red; 7.4: light blue) with and without AMF applications. The results are the average of at least two experiments with less than 8% error.
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Figure 4.  Release of antidepressant drugs (%: paroxetine, squares; duloxetine, red rhomboidal; vortioxetine, light blue circles) from the hydrogel PHE-Nip3 in buffered solutions (pH 4.60) 
with PBS (pH 7.40) pulsed variations of 2 h without (left panel) and with (right panel) AMF applications (20kHz/50W) at 25°C. The results are the average of at least two experiments with 
less than 3% error.
the ionized paroxetine has a greater capacity for ionic interaction with 
the COO- groups of the polymer as its basicity (pKa 9.77) is higher 
than that of the other two drugs (duloxetine, pKa 9.7; vortioxetine, 
pKa 8.85) [29]. Also, the hydrophobic effects and solubility of these 
drugs play a significant role in the release process, especially in pulsed 
processes involving changes in pH and swellability of the polymeric 
network. This trend is supported by the release data of the same drugs 
from hydrogel with weaker base strength (AVA-5). In fact, Figure 5 
reproduces, already from the first pulsed step, a release of paroxetine 
and duloxetine significantly higher than that observed for the hydrogel 
PHE-Nip3 under the same conditions. 
Moreover, the greater cross-linking of the AVA-5 hydrogel 
drastically reduces the burst release of the duloxetine at pH 4.60 that 
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values (pH 2.9 and 4.6) the pulsed release at physiological pH (pH 
7.4) of paroxetine is significantly higher in the presence of a low-
frequency AMF. The gradual and pulsed variation of the pH implies 
a swelling-collapsing mechanism of the hydrogel, which improves a 
higher release rate of the drug in dependence also on the time of the 
applied pulse. The pulsed release of duloxetine and vortioxetine show 
a closer paroxetine behaviour even if some observable differences are 
attributable to the lower basic strength and greater hydrophobicity of 
the drugs. These latter show a more weakly electrostatic interactions 
with the hydrogel and, consequently, are released with a higher rate. 
However, the mechanism by diffusion is insured in all cases when 
the swollen hydrogel to the pulse of pH 7.4 is then collapsed at a pH 
lower than critical. On the basis of these preliminary observations we 
conclude that the proposed polyelectrolytes hydrogel platforms can be 
used to design useful chrono-pharmacotherapeutic systems based on 
the circadian rhythm of the body [13-16,24]. Among these systems, 
one that may deserves a certain interest is the design of an artificial 
pancreas. To this purpose, a study for the release of insulin from smart 
hydrogels containing the immobilized enzyme glucose oxidase was 
undertaken for future outlook [34]. 
Experimental section
Materials and methods
The three antidepressant drugs used in this study were obtained 
by purification of commercial tablets in methanol solution. Similarly 
to paroxetine and duloxetine reported previously [9], the vortioxetine 
was extracted by the tablets of Brintellix 10 mg (H.Lundbeck A/5) in 
methanolic solution for 24 h under magnetic stirring. Subsequently, 
the solution was decanted and filtered over cotton. The dry product 
provided a fine white powder with consistent performance. Similarly, 
the three hydrogels used (PHE-Nip3, AVA-5 and AVA-2) have been 
reported previously with the loading of paroxetine and duloxetine by 
some of them [2,4,9,12]. Briefly, the hydrogel PHE-Nip3 consists of a 
practically becomes similar to paroxetine. On the other hand, the 
hydrogel with the lowest degree of cross-linking (AVA-2) [2,12] shows 
an initial release profile of vortioxetine which is higher than and in 
line with the general trend observed in all cases. The lower degree of 
cross-linking for the hydrogel AVA-2, resulting in greater swellability 
and comparable to the two values of pH 4.60 and pH pulsed 7.40, 
produces a release profile of vortioxetine significantly different from 
the other reported cases (Figure 5). This release becomes significantly 
more sustained for long periods and with less pulse effect. The degree 
of swelling (EDS) observed grows regularly with the successive pulses 
both at pH 4.60 and pH 7.40 because the hydrogel has never collapsed 
in any case; once again, the collapsing phenomenon occurs only for the 
hydrogel PHE-Nip3 that releases the drug, and at the various pH pulses 
it swells and collapses for the thermodynamic characteristics described 
above (Figure 6).
Conclusions
New stimuli-responsive hydrogels based on -amino acid residues 
can be considered as promising platforms for chrono-therapeutic 
applications, as they respond to external triggers [1,2,4,5,9-11]. The 
complications of circadian rhythms generally require a chrono-
pharmacotherapy which can be easily accomplished by means of a 
suitable pulsed drug delivery system [13-18]. The pulsed release of 
drugs is a new delivery system that certainly provides an increase in 
therapeutic benefit to patients suffering from chronic diseases, because 
it delivers the drug in the right amount at the right time and place. 
Though the possible biomedical applications are remarkable, in this 
study we wanted to preliminarily investigate the pulsed release of 
antidepressant drugs from two types of hydrogels bearing residues 
of L-phenylalanine (PHE-Nip3) and L-valine (AVA-5 and AVA-2 ). 
Unlike the simple hydrogel of AVA series which however is basically 
sensitive to variations in pH and temperature, the PHE-Nip3 hydrogel 
contains embedded magnetic nanoparticles that make it sensitive 
to further stimulation of AMF. In fact, at two different acidic pH 
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Figure 5.  Release (%) of: paroxetine (squares) and duloxetine (pink rhomboidal) from the hydrogel AVA-5; vortioxetine (light blue circles) from the hydrogel AVA-2 at 25°C and in buffered 
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copolymer of N-acryloyl-L-phenylalanine and N-isopropylacrylamide 
units (in a molar ratio 1 to 1) and cross-linked with 2 mol% of N,N’-
ethylene-bisacrylamide (EBA ); the cross-linking reaction was carried 
out in aqueous solution in the presence of cobalt ferrite CoFe2O4 
magnetic nanoparticles [6]. On the other hand, the two homopolymer 
hydrogels were obtained by radical reaction of N-acryloyl-L-valine in 
the presence of 2 mol% (AVA-2) and 5 mol% (AVA-5) of cross-linking 
agent EBA. The three buffer solutions were prepared at three different 
pHs and at ionic strength 0.15 mol/L NaCl. While the PBS solution at pH 
7.40 and the acetate solution at pH 4.60 were prepared according to the 
recipe shown in a previous work [9], the solution at pH 2.90 was made up 
of hydrochloric acid added to the saline solution by controlling the pH 
thoroughly with a pH-meter. The pH measurements were carried out 
with a potentiometric apparatus (TitraLab90, Radiometer Analytical) 
and automatically recorded with a Windows-based software (TimTalk 
9). A combined glass pH electrode (Red Rod) and a temperature sensor 
(T201) carefully measured the pH and the temperature of the solution 
[35]. Before each pH measurement, the apparatus was calibrated 
with two buffer solutions (Radiometer Analytical) at pH 4.01 and 
pH 7.00. The spectrophotometric measurements were made with a 
Specord 210 spectrophotometer (Analytik Jena) equipped with 10 
mm quartz cuvettes. In addition, the alternating magnetic field (AMF) 
measurements have been supported by an AG 1006 amplifier/generator 
(T&C Power Conversion, Inc., Rochester, NY, USA) operating at 50W 
and 20kHz of power and frequency, respectively; the cell used for 
this purpose has been previously described and consists of a solenoid 
winding with honeycomb cell [4].
Loading and release of the drug
The two hydrogels PHE-Nip3 and AVA-5 were loaded with 
paroxetine and duloxetine according to the procedure previously 
described [5,9]. The loading of vortioxetine on hydrogels PHE-Nip3 
and AVA-2 was conducted as follows. A weighed sample of dry 
hydrogel (PHE-Nip3, 100 mg; AVA-2, 50 mg) was swollen in distilled 
water containing a stoichiometric amount of sodium hydroxide. The 
fully swollen hydrogel was subsequently washed with distilled water 
and wiped with tissue paper. To the swollen hydrogel (EDS = 764 for 
PHE-Nip3 and 352 for AVA-2) a solution (20 mL) of vortioxetine (101 
mg for PHE-Nip3 and 174 mg for AVA-2), previously filtered on cotton, 
was added. The addition of the drug solution caused a prompt collapse 
of the drug-loaded hydrogel which, after a few minutes, produced a 
finely dispersed solid. The solid residue was filtered and rapidly washed 
with distilled water three times (EDS = 1.2 for PHE-Nip3 and 126.3 for 
AVA-2). After drying it in air and vacuum, the hydrogel provided an 
increase in weight consistent with the amount of loaded drug: PHE-
Nip3, 16.5 wt%; AVA-2, 34.3 wt%. 
Pulsed release of the three drugs from the hydrogels considered 
was carried out at 25°C using three buffer solutions at different pH 
(pH 2.9, 4.6, and 7.4). For PHE-Nip3 hydrogel loaded with the drug, a 
quantity of dry sample (4-10 mg) was weighed in a Strainer cell (pore 
size, 70 μm) and placed in 50 mL of the appropriate buffer at acidic pH 
(2.9 or 4.6) in a hermetically sealed plastic container and submitted 
to the AMF. A parallel control solution was prepared under the same 
conditions but without AMF. The amount of drug released at various 
set times was monitored spectrophotometrically by measuring the 
absorbance of the solution at 294 nm (for paroxetine), 290 nm (for 
duloxetine), and 227 nm (for vortioxetine). After three to four days 
of the observed slow release, the acid solution was rapidly replaced 
with 50 mL of PBS solution (pH 7.40); the Strainer cell containing the 
hydrogel was quickly washed in PBS and thoroughly wiped with tissue 
paper to measure the EDS value. The release of the drug was continued 
for a short period of one or two hours in PBS solution, measuring its 
absorbance value, and then resuming the initial acid pH solution to 
continue the release for further four days. Once again, the PBS solution 
was replaced for a short period of time and then placed in acid pH 
solution for further four days. The last substitution with the PBS 
solution continued the release of the drug for several days and until 
the drug completely discharged from the hydrogel that swelled to its 
maximum value under these experimental conditions. Obviously, at 
each step of replacing the PBS solution, weighing of the Strainer cell 
containing the hydrogel sample was carefully performed to determine 
the value of EDS. Similarly, but without the aid of the AMF, the pulsed 
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release of drugs from the hydrogels AVA-5 and AVA-2 was evaluated. 
The weighed sample quantities were 7-10 mg for AVA-5 and 5-6 mg 
for AVA-2. In all cases, at least two replicates for each sample were 
performed to evaluate drug release. The reproducibility of the results 
was always in good agreement. 
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